Health Canada approved Zepbound as the first medication in Canada to treat obstructive sleep apnea in adults living with obesity [1].
This approval marks a significant shift in treatment options for a patient population that previously relied primarily on mechanical interventions. By providing a pharmacologic alternative, the decision addresses a long-standing unmet medical need for those battling both obesity and sleep disorders [1], [2].
Zepbound, known generically as tirzepatide injection, was developed by Eli Lilly Canada [1]. The drug is specifically indicated for the treatment of moderate-to-severe obstructive sleep apnea in adults who are also living with obesity [1].
The announcement of the approval occurred on June 23, 2026 [1]. Until this point, pharmacological treatments for obstructive sleep apnea were not available in the Canadian market [1].
Obstructive sleep apnea occurs when the airway is partially or fully blocked during sleep, often exacerbated by excess weight around the neck and throat. While Continuous Positive Airway Pressure (CPAP) machines are the standard of care, many patients struggle with adherence to such devices [2].
The introduction of tirzepatide provides a new pathway for managing the condition by targeting the underlying obesity that often contributes to airway obstruction [2]. This medication is now available to eligible patients under the jurisdiction of Health Canada [1].
“Zepbound is the first-ever obstructive sleep apnea medication in Canada for adults living with obesity.”
The approval of tirzepatide for obstructive sleep apnea signals a transition toward treating the systemic causes of sleep disorders rather than just the symptoms. By targeting obesity—a primary driver of airway collapse—this medication may reduce the total reliance on CPAP machines and improve long-term health outcomes for high-risk adults.
